---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-064102"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2026-10-01T11:01:21+00:00"
generated_at: "2026-10-12T14:14:15.271564+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Foghorn, Lilly halt FHD-909 Phase 1 expansion; FHTX cuts 40% of staff, cash runway to 2H 2029

## Summary
- Foghorn and Eli Lilly will not advance FHD-909 (LY4050784) into the Phase 1 expansion phase after reviewing dose-escalation data; the selective SMARCA2 degrader program also ends.
- Workforce reduced by approximately 40%, with roughly 65 full-time employees expected after the cut; reduction substantially complete in Q4 2026.
- Charges of about $2.3 million, all future cash, primarily one-time severance and benefits in Q4 2026; runway extended into the second half of 2029.
- Remaining focus: selective EP300 degrader, novel oral immunology and inflammation program, selective CBP degrader, and induced proximity platform.
- CEO Adrian Gottschalk said SMARCA2/4 synthetic lethality biology did not translate into required efficacy; no further Lilly collaboration activities anticipated.

## SEC filing metadata
- accession: 0001628280-26-064102
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2026-10-01T11:01:21+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/0001628280-26-064102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828026064102/fhtx-20260925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-064102
- JSON: https://secwatch.observer/filing/0001628280-26-064102.json
- Plain text: https://secwatch.observer/filing/0001628280-26-064102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.